FYFV

Views & Analysis

Sustainability and Transformation Plans present an opportunity for pharma to support research into mental health conditions.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.